Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc., has broadened its manufacturing capabilities bringing online its new spray dryer following the successful installation and validation of the advanced manufacturing equipment at its UK-based site.
The contract development and manufacturing organisation (CDMO) has seen significant interest for its expanded offering from a range of drug development companies spanning specialty pharmaceutical companies to Big Pharma firms.
The new GEA PSD-1 spray dryer has completed validation testing, enabling the CDMO to scale-up early phase bench top processes to support later stage clinical development and niche, low volume manufacturing requirements.
Dr Nikin Patel, president at Juniper Pharma Services, said: “The final installation of the PSD-1 spray dryer marks a step change in our manufacturing capabilities and aligns well with our downstream roller compaction, tableting and encapsulation equipment.”
“The market response to our investment in our spray drying capabilities has been excellent both in the US and Europe. Not only does our extended capability provide clients with a very appealing scale to support their product development, it is also underpinned by a strong understanding of drug in polymer delivery systems derived from two decades of probing and resolving development issues for challenging products and processes.”
Designed for both aqueous and solvent based formulations, the PSD-1 extends Juniper’s spray drying capabilities by around 10 times. The technology enables the CDMO to provide clients with particle engineering alternatives and amorphous materials to help with solubility and bioavailability challenges.
Together with the company’s recent investments in downstream processing, Juniper Pharma Services now has an enhanced manufacturing capability to deliver optimised solid oral dose forms, that will provide scalable solutions for demanding products.
Supporting pharmaceutical and biotechnology companies worldwide, Juniper Pharma Services develops and produces oral and topical drug products.
Routinely dealing with compounds with significant formulation challenges, the CDMO’s team is able to optimise formulation performance through its science-led and consultative approach to projects.